All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Pro-doxorubicin
Therapeutic Area: Oncology Product Name: AVA6000
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Point Biopharma
Deal Size: $17.5 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 07, 2021
Details:
Deal provides POINT with license to pre|CISION technology for use in the first radiopharmaceutical prodrug the company intends to develop, and a non-exclusive license to the pre|CISION™ platform for the development of a broader pipeline of FAP-activated radiopharmaceuticals.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): FAP activated doxorubicin prodrug
Therapeutic Area: Oncology Product Name: AVA6000
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 23, 2020
Details:
The dose-escalation phase of the study, which will be carried out in 15-20 patients, is designed to evaluate the safety of AVA6000 in humans and establish the appropriate dosing levels for the dose expansion phase of the study.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): PLX4720,Talimogene laherparepvec,Antibodies
Therapeutic Area: Oncology Product Name: PLX4720
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Oracle Cancer Trust
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 09, 2020
Details:
The BRAF drug, called PLX4720, which targets this genetic mutation, was developed at the ICR, and produces significant results in both thyroid cancers and melanomas which carry the mutation.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): SOL-578
Therapeutic Area: Oncology Product Name: SOL-578
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: PharmaEngine
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration December 04, 2020
Details:
Under the terms of the Agreement, Sentinel Oncology will receive an exclusivity payment and PharmaEngine will obtain an option to receive the exclusive rights to develop and commercialize SOL-578 worldwide.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): BT7480
Therapeutic Area: Oncology Product Name: BT7480
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 09, 2020
Details:
New data presented at SITC demonstrate that treatment with BT7480 leads to significant modulation of the tumor microenvironment, including immune checkpoints. Finding supports potential dosing of BT7480 in combination with checkpoint inhibitors.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): KT-413
Therapeutic Area: Oncology Product Name: KT-413
Highest Development Status: Preclinical Product Type: Undisclosed
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 04, 2020
Details:
ABSTRACT “KTX-120, a Novel IRAKIMiD Degrader of IRAK4 and IMiD substrates shows Preferential Activity and Induces Regressions in MYD88-Mutant DLBCL CDX and PDX models,” presented by Duncan H. Walker, PhD, Vice President of Oncology at Kymera Therapeutics.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): STC-15
Therapeutic Area: Oncology Product Name: STC-15
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 22, 2020
Details:
STC-15 is an orally bioavailable, small molecule METTL3 inhibitor targeting an entirely new mechanism of action (modulation of RNA epigenetics) to treat acute myeloid leukaemia (AML) and other solid and haematological cancers.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): EPS 201
Therapeutic Area: Oncology Product Name: EPS 201
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Innovate UK
Deal Size: $1.3 million Upfront Cash: Undisclosed
Deal Type: Funding October 21, 2020
Details:
Epsilogen will collaborate with King’s College London (KCL) and use the funding from the grant to further develop the company’s novel cancer immunotherapeutic EPS 201.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): BT7480
Therapeutic Area: Oncology Product Name: BT7480
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 14, 2020
Details:
BT7480 is a novel, fully synthetic TICA targeting Nectin-4, agonizing CD137. EphA2/CD137 TICAs are comprised of Bicycles that target the tumor antigen EphA2, which is overexpressed in a range of solid tumor types and associated with poor outcomes.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): SDC-1802
Therapeutic Area: Oncology Product Name: SDC-1802
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 08, 2020
Details:
The patent will protect the SDC-1802 molecule and pharmaceutical preparations thereof. Subject to certain formalities being completed, the Company expects that the patent will be granted within three months.
Drugs in Development
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
